X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MYCO-006—MDMA-derived short-acting drug analogs (3,4-methylenedioxymethamphetamine) are designed for treating various conditions, including anxiety and pain.
Lead Product(s): Midomafetamine
Therapeutic Area: Psychiatry/Psychology Product Name: MYCO-006
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
MYCO-001 (psilocybin) in a recent Investigational New Drug (IND) application, marking the first clearance of the Company’s drug product, increases smoking abstinence compared to a placebo.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: MYCO-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2022
Details:
MYCO-001 (Psilocybin) assisted therapy has shown meaningful advantages over available medications for tobacco addiction including significant increases in safety and efficacy and for the indication of smoking cessation.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: MYCO-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johns Hopkins Psychedelic Research Group
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
Company rapidly prepares to submit IND and Breakthrough Therapy Status Application, after positive meeting with FDA for MYCO-001, Psilocybin-assisted therapy which has shown meaningful advantages over available medications for tobacco addiction.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: MYCO-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
MYCO-001 (psilocybin), a hallucinogenic alkaloid found in mushrooms will assess the safety and efficacy of psilocybin-assisted psychotherapy in a structured smoking cessation treatment program.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: MYCO-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johns Hopkins University
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2022
Details:
Under the partnership with Combat Stress, Mydecine will lead with drug candidate, MYCO-001, as an adjunct to psychotherapy to treat severe PTSD in veterans to utilize psilocybin, as part of a psychoactive-assisted psychotherapy treatment.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: MYCO-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Combat Stress
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 24, 2022
Details:
The new serotonin receptor model (5-HT2A) will allow the Company to rapidly increase drug analysis promoting near-term patent filings for novel psychedelic molecules for the treatment of mental health disorder.
Lead Product(s): Psychedelic Therapy
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
The application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of which are critical for use in the medical setting.
Lead Product(s): Psilocin
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021
Details:
The NIDA’s decision to fund the continuation of Dr. Johnson’s smoking cessation study is a strong validator of medicines, such as MYCO001 formulation, for the treatment of smoking cessation.
Lead Product(s): Psilocybine
Therapeutic Area: Psychiatry/Psychology Product Name: MYCO-001
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2021
Details:
MYCO-003 combines a serotonin agonist with a serotonin releasing agent, has the potential to reduce anxiety during therapy before needing to provide extensive supportive care, especially anxiety and post-traumatic stress disorder (PTSD).
Lead Product(s): MYCO-003
Therapeutic Area: Psychiatry/Psychology Product Name: MYCO-003
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
